Logistics and comparisons will bring growth down for Ambu, analyst says

Senior analyst at Sydbank Søren Løntoft Hansen has subdued expectations for the first quarter of medtech company Ambu.

Photo: Ambu / PR

The first quarter for the skewed 2021/2022 financial year will be marked by a difficult basis of comparison and continued logistical challenges, both of which will put a damper on the report, says Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank, prior to the report’s release on February 8.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs